Clinical trial · Interventional
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
Irinotecan And Cytarabine In Refractory or Relapsed Acute Myeloid Leukemia And In Chronic Myelogenous Leukemia In Myeloid Blast Transformation: Efficacy And In Vitro Correlates
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of combining irinotecan with cytarabine in treating patients who have refractory or recurrent acute myeloid leukemia or chronic myelogenous leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cytarabine | Drug | Cytarabine | ALIAS |
| irinotecan hydrochloride | Drug | Irinotecan | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed acute myeloid leukemia (M0-M7)
* De novo or secondary disease
* Previously treated and refractory to prior therapy (which has included high-dose cytarabine and an anthracycline)
* Antecedent hematologic disorders allowed OR
* Histologically confirmed Philadelphia chromosome-positive chronic myelogenous leukemia in myeloid blast transformation
* Treated or untreated
* Blast transformation defined by at least 20% blasts in marrow and/or blood
* Myeloid lineage defined by immunophenotyping
PATIENT CHARACTERISTICS:
Age
* 15 and over
Performance status
* 0-3
Life expectancy
* At least 4 weeks
Hematopoietic
* See Disease Characteristics
Hepatic
* Bilirubin less than 2 times upper limit of normal (ULN)
* SGOT less than 2 times ULN
Renal
* Creatinine less than 1.5 times ULN
Other
* Not pregnant or nursing
* Negative pregnancy test
* No other concurrent serious medical or psychiatric illness that would preclude study consent
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* See Disease Characteristics
* Prior chemotherapy for an antecedent malignancy or other medical condition allowed
Endocrine therapy
* Not specified
Radiotherapy
* Prior radiotherapy for an antecedent malignancy or other medical condition allowed
Surgery
* Not specifiedReferences
Publications (0)
Data not yet available